论文部分内容阅读
目的研究糖尿病肾病早期应用厄贝沙坦和黄芪注射液治疗的临床效果。方法选择2009年1月-2012年1月我科收治的糖尿病肾病早期患者112例,随机分成对照组和治疗组各56例,在常规治疗的同时,对照组使用厄贝沙坦,治疗组使用厄贝沙坦和黄芪注射液,比较两组治疗后24h尿蛋白、血肌酐和尿素氮及β2微球蛋白的变化程度。结果两组患者治疗后24h尿蛋白、血肌酐和β2微球蛋白均较治疗前下降,差异有统计学意义(P<0.05);治疗组较对照组下降明显,差异有统计学意义(P<0.05)。结论糖尿病肾病早期应用厄贝沙坦和黄芪注射液治疗能明显改善患者的肾功能、减少尿蛋白的含量,有效缓解糖尿病肾病的症状,延缓疾病的进展。
Objective To study the clinical effect of irbesartan and astragalus injection in the early stage of diabetic nephropathy. Methods From January 2009 to January 2012, 112 patients with diabetic nephropathy who were admitted to our department were randomly divided into control group and treatment group (n = 56) each. In the same time, irbesartan was used in the control group and in the treatment group Irbesartan and Astragalus injection, 24 hours after treatment, urinary protein, serum creatinine and urea nitrogen and β2 microglobulin changes. Results The levels of urinary protein, serum creatinine and β2 microglobulin in 24 hours after treatment in both groups were significantly lower than those before treatment (P <0.05). The treatment group decreased significantly compared with the control group (P < 0.05). Conclusion The early application of irbesartan and astragalus injection in diabetic nephropathy can significantly improve renal function, reduce urinary protein content, effectively relieve the symptoms of diabetic nephropathy and delay the progression of the disease.